AlphaStocks
4.9
Weak

RESMED INC (RMD)

Health Care / Health Care Equipment

S&P 500

$209.79

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#594out of 1126 in Health Care

Is RESMED INC a Good Investment in 2026?

RESMED INC (RMD) scores 4.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates RESMED INC as Strong (8/9). The Lynch model is the least favorable, rating it Neutral. RESMED INC currently trades below its estimated fair value of $287, suggesting potential upside. RESMED INC ranks #594 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E22.1ROE23.6Market Cap31BDiv Yield1.0

Estimated Fair Value

$286.6927% below

Fair value above market price. EPS grew 37% year-over-year. ROE of 24% signals strong profitability. P/E of 22x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 1.5 · Fast Grower

Greenblatt

Attractive

Top 25% (rank 19%)

Frequently Asked Questions

Is RESMED INC (RMD) a good investment?
Based on AlphaStocks' composite analysis, RESMED INC (RMD) scores 4.9 out of 10, earning a Weak rating. This score is below average, suggesting caution. Fair value above market price. EPS grew 37% year-over-year. ROE of 24% signals strong profitability. P/E of 22x is moderate for this quality level.
What is RESMED INC's Piotroski F-Score?
RESMED INC's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RMD overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $287, RMD appears undervalued. The stock currently trades 27% below its estimated fair value. Fair value above market price. EPS grew 37% year-over-year. ROE of 24% signals strong profitability. P/E of 22x is moderate for this quality level.
How does RMD compare to other Health Care stocks?
RESMED INC ranks #594 out of 1126 stocks in the Health Care sector, placing it in the top 53% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about RMD?
AlphaStocks evaluates RMD using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 4.9/10.

Similar Stocks

PARRAZNFTI

Compare RMD with

RMD vs PARRRMD vs AZNRMD vs FTI

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer